Efficacy and Safety of Triple Antiplatelet Therapy With and Without Concomitant Anticoagulation During Elective Percutaneous Coronary Intervention (the REMOVE Trial)

American Journal of Cardiology

Volumn 100, Issue 7, 2007, Pages 1099-1102

  Valencia, Rafael ^a   Price, Matthew J ^a   Sawhney, Neil ^a   Lee, Steve S ^a   Wong, Garrett B ^a   Gollapudi, Raghava R ^a   Banares, Michelle ^a   Schatz, Richard A ^a   Teirstein, Paul S ^a  

^a SCRIPPS CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ANTICOAGULANT AGENT; ANTITHROMBOCYTIC AGENT; CLOPIDOGREL; EPTIFIBATIDE; FIBRINOGEN RECEPTOR ANTAGONIST; HEPARIN;

ADULT; AGED; ANTICOAGULANT THERAPY; ANTICOAGULATION; ARTICLE; BLEEDING; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORONARY ARTERY DISEASE; DRUG EFFICACY; DRUG SAFETY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; PERCUTANEOUS CORONARY INTERVENTION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; THROMBOEMBOLISM; TREATMENT OUTCOME;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANGIOPLASTY, TRANSLUMINAL, PERCUTANEOUS CORONARY; ANTICOAGULANTS; ASPIRIN; CORONARY ARTERIOSCLEROSIS; DRUG THERAPY, COMBINATION; FEMALE; HEPARIN; HUMANS; MALE; MIDDLE AGED; PEPTIDES; PILOT PROJECTS; PLATELET AGGREGATION INHIBITORS; PROSPECTIVE STUDIES; PYRIDINES; TICLOPIDINE; TREATMENT OUTCOME;

EID: 34548634592     PISSN: 00029149     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.amjcard.2007.04.057     Document Type: Article

References (20)

1. Landefeld C.S., Anderson P.A., Goodnough L.T., Moir T.W., Hom D.L., Rosenblatt M.W., and Goldman L. The bleeding severity index: validation and comparison to other methods for classifying bleeding complications of medical therapy. J Clin Epidemiol 42 (1989) 711-718
2. ESPRIT Investigators. Enhanced Suppression of the Platelet IIb/IIIa Receptor with Integrilin Therapy. Novel dosing regimen of eptifibatide in planned coronary stent implantation (ESPRIT): a randomised, placebo-controlled trial. Lancet 356 (2000) 2037-2044
3. Lincoff A.M., Bittl J.A., Harrington R.A., Feit F., Kleiman N.S., Jackman J.D., Sarembock I.J., Cohen D.J., Spriggs D., Ebrahimi R., et al., REPLACE-2 Investigators. Bivalirudin and provisional glycoprotein IIb/IIIa blockade compared with heparin and planned glycoprotein IIb/IIIa blockade during percutaneous coronary intervention: REPLACE-2 randomized trial. JAMA 289 (2003) 853-863
4. Denardo S.J., Davis K.E., and Tcheng J.E. Elective percutaneous coronary intervention using broad-spectrum antiplatelet therapy (eptifibatide, clopidogrel, and aspirin) alone, without scheduled unfractionated heparin or other antithrombin therapy. Am Heart J 149 (2005) 138-144
5. Cote A.V., Berger P.B., Holmes Jr. D.R., Scott C.G., and Bell M.R. Hemorrhagic and vascular complications after percutaneous coronary intervention with adjunctive abciximab. Mayo Clin Proc 76 (2001) 890-896
6. Bhatt D.L., Lee B.I., Casterella P.J., Pulsipher M., Rogers M., Cohen M., Corrigan V.E., Ryan Jr. T.J., Breall J.A., Moses J.W., et al., Coronary Revascularization Using Integrilin and Single bolus Enoxaparin Study. Safety of concomitant therapy with eptifibatide and enoxaparin in patients undergoing percutaneous coronary intervention: results of the Coronary Revascularization Using Integrilin and Single bolus Enoxaparin Study. J Am Coll Cardiol 41 (2003) 20-25
7. Denardo S.J., Davis K.E., Reid P.R., and Tcheng J.E. Efficacy and safety of minimal dose (≤1,000 units) unfractionated heparin with abciximab in percutaneous coronary intervention. Am J Cardiol 91 (2003) 1-5
8. Tolleson T.R., O'Shea J.C., Bittl J.A., Hillegass W.B., Williams K.A., Levine G., Harrington R.A., and Tcheng J.E. Relationship between heparin anticoagulation and clinical outcomes in coronary stent intervention: observations from the ESPRIT trial. J Am Coll Cardiol 41 (2003) 386-393
9. Xiao Z., and Theroux P. Platelet activation with unfractionated heparin at therapeutic concentrations and comparisons with a low-molecular-weight heparin and with a direct thrombin inhibitor. Circulation 97 (1998) 251-256
10. Brieger D.B., Mak K.H., Kottke-Marchant K., and Topol E.J. Heparin-induced thrombocytopenia. J Am Coll Cardiol 31 (1998) 1449-1459
11. Davoren A., and Aster R.H. Heparin-induced thrombocytopenia and thrombosis. Am J Hematol 81 (2006) 36-44
12. Kinnaird T.D., Stabile E., Mintz G.S., Lee C.W., Canos D.A., Gevorkian N., Pinnow E.E., Kent K.M., Pichard A.D., Satler L.F., et al. Incidence, predictors, and prognostic implications of bleeding and blood transfusion following percutaneous coronary interventions. Am J Cardiol 92 (2003) 930-935
13. Attubato M.J., Feit F., Bittl J.A., Chew D., and Lincoff A.M. Major hemorrhage is an independent predictor of 1-year mortality following percutaneous coronary intervention: an analysis from REPLACE-2. Am J Cardiol 946 suppl 1 (2004) 39E
14. Rao S.V., O'Grady K., Pieper K.S., Granger C.B., Newby L.K., Van de Werf F., Mahaffey K.W., Califf R.M., and Harrington R.A. Impact of bleeding severity on clinical outcomes among patients with acute coronary syndromes. Am J Cardiol 96 (2005) 1200-1206
15. Cohen D.J., Lincoff A.M., Lavelle T.A., Chen H.L., Bakhai A., Berezin R.H., Jackman D., Sarembock I.J., and Topol E.J. Economic evaluation of bivalirudin with provisional glycoprotein IIB/IIIA inhibition versus heparin with routine glycoprotein IIB/IIIA inhibition for percutaneous coronary intervention: results from the REPLACE-2 trial. J Am Coll Cardiol 44 (2004) 1792-1800
16. Steigen T.K., Maeng M., Wiseth R., Erglis A., Kumsars I., Narbute I., Gunnes P., Mannsverk J., Meyerdierks O., Rotevatn S., et al., Nordic PCI Study Group. Randomized study on simple versus complex stenting of coronary artery bifurcation lesions: the Nordic bifurcation study. Circulation 114 (2006) 1955-1961
17. Chieffo A., Bonizzoni E., Orlic D., Stankovic G., Rogacka R., Airoldi F., Mikhail G.W., Montorfano M., Michev I., Carlino M., and Colombo A. Intraprocedural stent thrombosis during implantation of sirolimus-eluting stents. Circulation 109 (2004) 2732-2736
18. Kandzari D.E., Berger P.B., Kastrati A., Steinhubl S.R., Mehilli J., Dotzer F., Ten B.J.M., Neumann F.J., Bollwein H., Dirschinger J., Schomig A., and ISAR-REACT Study Investigators. Influence of treatment duration with a 600-mg dose of clopidogrel before percutaneous coronary revascularization. J Am Coll Cardiol 44 (2004) 2133-2136
19. Patti G., Colonna G., Pasceri V., Pepe L.L., Montinaro A., and Di Sciascio G. Randomized trial of high loading dose of clopidogrel for reduction of periprocedural myocardial infarction in patients undergoing coronary intervention: results from the ARMYDA-2 (Antiplatelet therapy for Reduction of MYocardial Damage during Angioplasty) study. Circulation 111 (2005) 2099-2106
20. Price M.J., Coleman J.L., Steinhubl S.R., Wong G.B., Cannon C.P., and Teirstein P.S. Onset and offset of platelet inhibition after high-dose clopidogrel loading and standard daily therapy measured by a point-of-care assay in healthy volunteers. Am J Cardiol 98 (2006) 681-684